科伦药业(002422) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 6,219,417,413, representing a 10.32% increase compared to CNY 5,601,800,088 in the same period last year[5]. - Net profit attributable to shareholders was CNY 1,026,188,176, marking a 26.00% increase from CNY 810,322,186 in the previous year[5]. - The net profit after deducting non-recurring gains and losses was CNY 992,050,869, up 25.67% from CNY 789,342,327 year-on-year[5]. - Basic earnings per share increased to CNY 0.67, a rise of 17.54% from CNY 0.56 in the same quarter last year[5]. - Operating profit for the period was CNY 1,632,448,204, up 44.7% from CNY 1,127,604,827 in the previous year[29]. - Net profit attributable to the parent company was CNY 1,026,188,176, representing a 26.1% increase from CNY 814,451,530 in Q1 2023[29]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 37,676,458,365, reflecting a 3.35% increase from CNY 36,454,901,140 at the end of the previous year[5]. - Total liabilities decreased to CNY 11,804,006,037 from CNY 13,439,307,574 in the previous year[26]. - The company’s total equity attributable to shareholders increased by 13.16% to CNY 22,260,402,452 from CNY 19,672,377,989 at the end of the previous year[5]. Cash Flow - Cash flow from operating activities decreased by 15.11% to CNY 1,278,763,116 compared to CNY 1,511,963,345 in the previous year[5]. - Operating cash inflow totaled 6,561,069,026.00 yuan, down 6.67% from 7,027,731,678.00 yuan in the previous period[30]. - Net cash flow from operating activities decreased to 1,278,763,116.00 yuan from 1,506,360,831.00 yuan, a decline of 15.14%[30]. - Net cash flow from investing activities improved to 670,633,809.00 yuan from a negative 466,854,805.00 yuan, indicating a significant turnaround[31]. - Cash and cash equivalents rose to CNY 6,288,440,847, compared to CNY 4,675,476,376 at the start of the quarter, representing an increase of about 34.4%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 29,266[13]. - Liu Gexin holds 23.67% of shares, totaling 379,128,280 shares, with 126,703,399 shares pledged[13]. - The second largest shareholder, Yaan State-owned Assets Management Co., Ltd., holds 5.86% of shares, totaling 93,801,074 shares, with 30,890,000 shares pledged[13]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding nearly 24%[13]. Research and Development - Research and development expenses were CNY 502,816,867, slightly up from CNY 491,663,538 in Q1 2023[28]. - The company has received drug registration approval for its oral medication, Aicuo Poma Ethanolamine Tablets, which is the first global treatment for ITP, offering more convenience and significantly reducing bleeding rates compared to injection therapies[20]. - The company’s subsidiary, Hunan Kelun Pharmaceutical Co., Ltd., has received drug registration approval for Olaparib Tablets, the first marketed PARP inhibitor, showing a median overall survival benefit of over 6 years for patients with HRD-positive ovarian cancer[20]. Financial Management - The company reported a significant decrease in financial expenses by 82.43%, down to CNY 16,831,296 from CNY 95,813,548 due to reduced financing amounts and lower interest rates[10]. - The total amount of entrusted wealth management products purchased during the reporting period was RMB 540 million, with an expected return rate of 3.10%[18]. - The actual income from entrusted wealth management during the reporting period was RMB 421.27 million, with actual losses amounting to RMB 178.81 million[18]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance growth[29]. - The report does not indicate any new strategies or product developments during the quarter[17]. - There is no mention of market expansion or mergers and acquisitions in the current report[17].